Gilead Sciences Inc (GILD)

07:39 AM

AmBisome Market 2025 Is Booming Worldwide by 2032 |Gilead Sciences Inc and Astellas Pharma Inc - openPR.com

07:39 AM

07:28 AM

Using data tools to time your Gilead Sciences Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com

07:28 AM

05:49 AM

Is Gilead Sciences Inc. stock cheap at current valuation2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com

05:49 AM

02:50 AM

François Cherifi: Deeply Grateful to Gilead Sciences for Awarding me the Gilead Scholarship at ESMO2025 - Oncodaily

02:50 AM

Oct 27, 2025

Exit strategy if you’re trapped in Gilead Sciences Inc.July 2025 Gainers & Growth Focused Entry Reports - newser.com

Oct 27, 2025

Oct 27, 2025

Is this a good reentry point in Gilead Sciences Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com

Oct 27, 2025

Oct 27, 2025

Is Gilead Sciences Inc. stock attractive for long term wealth buildingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - Fundação Cultural do Pará

Oct 27, 2025

Oct 27, 2025

Gilead Sciences’ GS-1219 HIV Study Update: Implications for Investors - TipRanks

Oct 27, 2025

Oct 27, 2025

What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView

Oct 27, 2025

Oct 27, 2025

Will Gilead Sciences Inc. stock remain a Wall Street favoriteMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com

Oct 27, 2025

Oct 27, 2025

Gilead Sciences: Strong Market Position and Growth Potential in HIV and PrEP with Promising Yeztugo Launch - TipRanks

Oct 27, 2025

Oct 27, 2025

Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com

Oct 27, 2025

Oct 27, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitMarket Rally & High Accuracy Trade Signal Alerts - newser.com

Oct 27, 2025

Oct 27, 2025

Will Gilead Sciences Inc. outperform the marketEarnings Growth Report & Expert Verified Movement Alerts - newser.com

Oct 27, 2025

Oct 27, 2025

Is Gilead Sciences Inc. still worth holding after the dip2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com

Oct 27, 2025

Oct 27, 2025

Gilead Sciences VP Praises China's Reforms for Helping Launch More Novel Drugs - Yicai Global

Oct 27, 2025

Oct 27, 2025

Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a buy for dividend portfolios2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com

Oct 27, 2025

Oct 26, 2025

What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsPortfolio Risk Summary & Real-Time Market Trend Scan - newser.com

Oct 26, 2025

Oct 26, 2025

How to build a dashboard for Gilead Sciences Inc. stockShare Buyback & Daily Profit Focused Screening - newser.com

Oct 26, 2025

Oct 26, 2025

Using economic indicators to assess Gilead Sciences Inc. potential2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com

Oct 26, 2025

Oct 26, 2025

Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Summary Report & Verified High Yield Trade Plans - newser.com

Oct 26, 2025

Oct 26, 2025

Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics - Markets Mojo

Oct 26, 2025

Oct 25, 2025

Florida Settlement with Gilead Sciences for Improper Promotion of HIV Drugs - West Orlando News

Oct 25, 2025

Oct 25, 2025

Chart based exit strategy for Gilead Sciences Inc.Market Performance Summary & AI Forecasted Entry and Exit Points - newser.com

Oct 25, 2025

Oct 25, 2025

Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025

Oct 24, 2025

Morgan Stanley Remains Bullish on Gilead Sciences (GILD) - MSN

Oct 24, 2025

Oct 24, 2025

What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha

Oct 24, 2025

Oct 24, 2025

Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech

Oct 24, 2025

Oct 24, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

Oct 24, 2025

Oct 23, 2025

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com

Oct 23, 2025

Oct 23, 2025

Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com

Oct 23, 2025

Oct 23, 2025

TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 - GuruFocus

Oct 23, 2025

Oct 23, 2025

Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe

Oct 23, 2025

Oct 23, 2025

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance

Oct 23, 2025

Oct 23, 2025

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025

Oct 23, 2025

Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener

Oct 23, 2025

Oct 23, 2025

TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener

Oct 23, 2025

Oct 23, 2025

Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com

Oct 23, 2025

Oct 23, 2025

Gilead to present liver disease data at AASLD conference - StreetInsider

Oct 23, 2025

Oct 23, 2025

(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire

Oct 23, 2025

Oct 22, 2025

CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus

Oct 22, 2025

Oct 22, 2025

Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus

Oct 22, 2025

Oct 22, 2025

Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha

Oct 22, 2025

Oct 22, 2025

Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com

Oct 22, 2025